Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial
Frontiers in Endocrinology · 2025
DOI: 10.3389/fendo.2025.1699591 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Endocrinology, 2025. Verfasst von Takeshi Osonoi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Naka Kinen Clinic, Ibaraki, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Erythrocytes, Hypoglycemic Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Imeglimin is a novel type 2 diabetes (T2D) drug that is expected to improve mitochondrial function. In phase 3 trials, imeglimin demonstrated a gradual reduction in hemoglobin A1c (HbA1c), with a plateau at approximately 20–24 weeks. As erythrocyte lifespan may affect HbA1c accuracy, this clinical trial aimed to evaluate the potential discordance between HbA1c and other glycemic markers following imeglimin therapy and to explore whether imeglimin affects erythrocytes.
Methods
This was a prospective, single-arm, open-label exploratory clinical trial (INFINITY study) conducted at Naka Kinen Clinic, Japan. Twenty-nine Japanese patients with inadequately controlled T2D received imeglimin 2,000 mg/day for six months. The primary endpoint was the change in hemoglobin concentration from baseline to Month 6. Secondary endpoints included serial changes in HbA1c, glycoalbumin (GA), 1,5-anhydroglucitol (1,5-AG), and erythrocyte lifespan, as well as comparison of glycemic reduction rates across these markers.
Results
The change in hemoglobin concentration at 6 months was not statistically significant (mean ± SD: −0.2 ± 0.9 g/dL; p = 0.23). While HbA1c and GA decreased and 1,5-AG increased one month after imeglimin initiation, GA and 1,5-AG showed rapid changes compared to the gradual decrease in HbA1c. The divergence in reduction rates between HbA1c and the other markers persisted for up to two months. When erythrocyte lifespan was assessed using 3-month interval averages, significant prolongation was observed in both the 1–3 month and 4–6 month periods compared to the pre-treatment period (−2 to 0 months).
Conclusion
This exploratory clinical trial suggests that imeglimin may prolong erythrocyte lifespan, resulting in disproportionately elevated HbA1c levels relative to true glycemic status. Reliance on HbA1c alone may underestimate imeglimin’s early glycemic effects, highlighting the value of alternative markers such as GA and 1,5-AG. Clinical trial registration https://jrct.mhlw.go.jp/latest-detail/jRCTs031220489 , Identifier jRCTs031220489.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Naka Kinen Clinic, Ibaraki, Japan.
- Research Administration Center, Saitama Medical University, Saitama, Japan.
Zitieren
APA
Osonoi, T., Shirabe, S., Saito, M., Hosoya, M., Watahiki, N., Shiozawa, N., Douguchi, S., Ofuchi, K., & Katoh, M. (2025). Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1699591
Vancouver
Osonoi T, Shirabe S, Saito M, Hosoya M, Watahiki N, Shiozawa N, et al. Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial. Frontiers in Endocrinology. 2025. doi:10.3389/fendo.2025.1699591
BibTeX
@article{Osonoi2025,
author = {Osonoi, Takeshi and Shirabe, Shinichiro and Saito, Miyoko and Hosoya, Mitsuru and Watahiki, Norie and Shiozawa, Nana and Douguchi, Satako and Ofuchi, Kensuke and Katoh, Makoto},
title = {Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial},
journal = {Frontiers in Endocrinology},
year = {2025},
doi = {10.3389/fendo.2025.1699591}
}
EUVIMED